Baird downgraded Oscar Health (OSCR) to Neutral from Outperform with a price target of $14, down from $28.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Moderately bullish activity in Oscar Health with shares up 1.8%
- Largest borrow rate increases among liquid names
- Oscar Health Faces Financial Instability Amid Pricing Challenges and Revised Earnings Expectations
- Oscar Health price target lowered to $11 from $17 at Barclays
- Oscar Health raises FY25 revenue view to $12.0B-$12.2B from $11.2B-$11.3B